IBIO - יחס חוב להיוון בספרים iBio Inc

iBio, Inc. (IBIO) faces challenges regarding its strategic pivot and rapid cash burn, as evidenced by the company's total debt-to-equity ratio on this GURU.Markets service chart, where the 0.03 mark characterizes this parameter. Proprietary protein synthesis methods create significant barriers to entry. The business is currently implementing AI to accelerate the discovery of therapeutic antibodies in immuno-oncology.

A conservative approach requires strict control of the debt load relative to the value of net assets. This metric compares total liabilities with book capitalization, revealing the extent of the business's dependence on borrowed funds. By analyzing the capital structure trend of debt to book capitalization, an investor assesses the company's insolvency risk. For iBio, Inc. (IBIO), this indicator is critical due to the lack of merger prospects and dependence on future licenses. High volatility of this metric underscores the fragility of the biotech startup's financial stability.